Abe H - Search Results

1

Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma.

Toyoda H, Kanneganti M, Melendez-Torres J, Parikh ND, Jalal PK, Piñero F, Mendizabal M, Ridruejo E, Cheinquer H, Casadei-Gardini A, Weinmann A, Peck-Radosavljevic M, Dufour JF, Radu P, Shiha G, Soliman R, Sarin SK, Kumar M, Wang JH, Tangkijvanich P, Sukeepaisarnjaroen W, Atsukawa M, Uojima H, Nozaki A, Nakamuta M, Takaguchi K, Hiraoka A, Abe H, Matsuura K, Watanabe T, Shimada N, Tsuji K, Ishikawa T, Mikami S, Itobayashi E, Singal AG, Johnson PJ. Toyoda H, et al. Among authors: abe h. Clin Gastroenterol Hepatol. 2024 Jan;22(1):72-80.e4. doi: 10.1016/j.cgh.2023.06.026. Epub 2023 Jul 11. Clin Gastroenterol Hepatol. 2024. PMID: 37442316

2

Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo.

Abe H, Yoshizawa K, Kitahara T, Aizawa R, Matsuoka M, Aizawa Y. Abe H, et al. J Gastroenterol. 2008;43(12):967-74. doi: 10.1007/s00535-008-2264-8. Epub 2008 Dec 24. J Gastroenterol. 2008. PMID: 19107341

3

Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.

Yoshizawa K, Abe H, Aida Y, Ishiguro H, Ika M, Shimada N, Tsubota A, Aizawa Y. Yoshizawa K, et al. Among authors: abe h. J Med Virol. 2013 Jul;85(7):1180-90. doi: 10.1002/jmv.23597. J Med Virol. 2013. PMID: 23918536

4

Serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic HCV genotype 1b infection.

Aizawa Y, Shimada N, Abe H, Seki N, Aida Y, Ishiguro H, Ika M, Kato K, Tsubota A. Aizawa Y, et al. Among authors: abe h. Hepat Mon. 2013 May 27;13(5):e8988. doi: 10.5812/hepatmon.8988. eCollection 2013 May. Hepat Mon. 2013. PMID: 23967025 Free PMC article.

5

Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.

Tsubota A, Shimada N, Atsukawa M, Abe H, Kato K, Ika M, Matsudaira H, Nagatsuma K, Matsuura T, Aizawa Y. Tsubota A, et al. Among authors: abe h. J Gastroenterol Hepatol. 2014 Jan;29(1):144-50. doi: 10.1111/jgh.12402. J Gastroenterol Hepatol. 2014. PMID: 24117654

6

α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype.

Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y. Shimada N, et al. Among authors: abe h. J Med Virol. 2014 Mar;86(3):461-72. doi: 10.1002/jmv.23824. Epub 2013 Oct 28. J Med Virol. 2014. PMID: 24166425

7

A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study.

Shimada N, Tsubota A, Atsukawa M, Abe H, Ide T, Takaguchi K, Chuganji Y, Toyoda H, Yoshizawa K, Ika M, Sato Y, Kato K, Kumada T, Sakamoto C, Aizawa Y, Sata M. Shimada N, et al. Among authors: abe h. Hepatol Res. 2014 Dec;44(14):E386-96. doi: 10.1111/hepr.12323. Epub 2014 Apr 15. Hepatol Res. 2014. PMID: 24606109

8

Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype.

Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y. Abe H, et al. Hepatol Res. 2015 Apr;45(4):387-96. doi: 10.1111/hepr.12360. Epub 2014 Jul 18. Hepatol Res. 2015. PMID: 24849518

9

Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C.

Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Nakagawa A, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C. Atsukawa M, et al. Among authors: abe h. Dig Liver Dis. 2014 Aug;46(8):738-43. doi: 10.1016/j.dld.2014.05.004. Epub 2014 May 29. Dig Liver Dis. 2014. PMID: 24880716

10

Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients.

Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y. Abe H, et al. Gastroenterol Res Pract. 2014;2014:549709. doi: 10.1155/2014/549709. Epub 2014 Aug 14. Gastroenterol Res Pract. 2014. PMID: 25197269 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,228 results

Search Page